Sorrento Therapeutics Analyst Ratings
Sorrento Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/02/2022 | 216.46% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
| 03/25/2022 | 1165.82% | HC Wainwright & Co. | $26 → $20 | Maintains | Buy |
| 08/09/2021 | 1545.57% | HC Wainwright & Co. | $30 → $26 | Maintains | Buy |
| 01/21/2021 | 2115.19% | Alliance Global Partners | → $35 | Initiates Coverage On | → Buy |
| 07/31/2020 | 1798.73% | HC Wainwright & Co. | $24 → $30 | Maintains | Buy |
| 05/26/2020 | 1418.99% | Dawson James | → $24 | Initiates Coverage On | → Buy |
| 03/30/2020 | 1418.99% | HC Wainwright & Co. | $28 → $24 | Reiterates | → Buy |
| 10/07/2019 | 1229.11% | JMP Securities | → $21 | Initiates Coverage On | → Market Outperform |
| 03/20/2019 | 659.49% | B. Riley Securities | $10.5 → $12 | Maintains | Buy |
| 06/28/2018 | 801.9% | B. Riley Securities | → $14.25 | Initiates Coverage On | → Buy |
| 04/03/2018 | 2431.65% | HC Wainwright & Co. | $38 → $40 | Maintains | Buy |
| 11/15/2017 | 279.75% | Oppenheimer | $7 → $6 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 11/02/2022 | 216.46% | 康託·菲茨傑拉德 | →$5 | 開始承保 | →超重 |
| 03/25/2022 | 1165.82% | HC Wainwright公司 | $26→$20 | 維護 | 買 |
| 08/09/2021 | 1545.57% | HC Wainwright公司 | $30→$26 | 維護 | 買 |
| 2021/01/21 | 2115.19% | 聯盟全球合作夥伴 | →$35 | 開始承保 | →購買 |
| 07/31/2020 | 1798.73% | HC Wainwright公司 | $24→$30 | 維護 | 買 |
| 05/26/2020 | 1418.99% | 道森·詹姆斯 | →$24 | 開始承保 | →購買 |
| 03/30/2020 | 1418.99% | HC Wainwright公司 | $28→$24 | 重申 | →購買 |
| 2019/07/10 | 1229.11% | JMP證券 | →$21 | 開始承保 | →市場跑贏大盤 |
| 2019/03/20 | 659.49% | B.萊利證券 | $10.5→$12 | 維護 | 買 |
| 2018/06/28 | 801.9% | B.萊利證券 | →$14.25 | 開始承保 | →購買 |
| 2018年03月04日 | 2431.65% | HC Wainwright公司 | $38→$40 | 維護 | 買 |
| 2017年11月15日 | 279.75% | 奧本海默 | $7→$6 | 維護 | 跑贏大盤 |
Sorrento Therapeutics Questions & Answers
索倫託治療公司問答
The latest price target for Sorrento Therapeutics (NASDAQ: SRNE) was reported by Cantor Fitzgerald on November 2, 2022. The analyst firm set a price target for $5.00 expecting SRNE to rise to within 12 months (a possible 216.46% upside). 2 analyst firms have reported ratings in the last year.
索倫託治療公司(納斯達克：SRNE)的最新目標價是由坎託·菲茨傑拉德於2022年11月2日報道的。這家分析公司將目標價定為5美元，預計SRNE將在12個月內升至(可能上漲216.46%)。去年有兩家分析公司公佈了評級。
The latest analyst rating for Sorrento Therapeutics (NASDAQ: SRNE) was provided by Cantor Fitzgerald, and Sorrento Therapeutics initiated their overweight rating.
索倫託治療公司(納斯達克代碼：SRNE)的最新分析師評級由坎託·菲茨傑拉德提供，索倫託治療公司啟動了他們的增持評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sorrento Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sorrento Therapeutics was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與索倫託治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。索倫託治療公司的上一次評級是在2022年11月2日提交的，所以你應該預計下一次評級將在2023年11月2日左右的某個時候提供。
While ratings are subjective and will change, the latest Sorrento Therapeutics (SRNE) rating was a initiated with a price target of $0.00 to $5.00. The current price Sorrento Therapeutics (SRNE) is trading at is $1.58, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的索倫託治療公司(SRNE)評級是以0.00美元至5.00美元的目標價啟動的。索倫託治療公司(SRNE)目前的交易價格為1.58美元，在分析師的預測範圍內。